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Abstract 
The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with 
mantle cell lymphoma (MCL) treated within two randomized trials of the European MCL 
Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment 
106/190 evaluable patients (56%) achieved a molecular remission (MR) based upon blood 
and/or bone marrow (BM) analysis. MR resulted in a significantly improved response 
duration (RD) (87% vs. 61% patients in remission at 2 years, p=0.0043) and emerged to be 
an independent prognostic factor for RD (HR 0.4, 95%CI 0.1-0.9, p=0.027). MR was highly 
predictive for prolonged RD independent of clinical response (CR, CRu, PR) (RD at 2 years: 
100% in BM MRD-negative CR and 88% in BM MRD-negative CRu/PR, compared to 78% in 
BM MRD-positive CR and 53% in BM MRD-positive CRu/PR, p=0.0015). Sustained MR 
during the post-induction period was predictive for outcome in MCL Younger after ASCT (RD 
at 2 years 100% vs. 65%, p=0.0007) and during maintenance in MCL Elderly (RD at 2 years: 
76% vs. 36%, p=0.015). ASCT in MCL Younger patients increased the proportion of patients 
in MR from 55% prior to high dose therapy to 72% thereafter. Sequential MRD monitoring is 
a powerful predictor for treatment outcome in MCL. 
 
 
 
Keywords: mantle cell lymphoma, autologous stem cell transplantation, RQ-PCR, minimal 
residual disease, MRD, immunochemotherapy 
 
 
 
 
 3
Introduction   
Mantle cell lymphoma (MCL) is characterized by a mostly advanced stage of disease at 
diagnosis and an aggressive clinical course with a short median overall survival (OS) of 3-4 
years after standard treatment. However, recent studies have reported an improved outcome 
with an almost doubled median survival of 5-6 years.1;2 The biological hallmark of MCL is the 
chromosomal translocation t(11;14)(q13;q32) leading to cyclin D1 protein overexpression. 
The translocation is detectable by molecular cytogenetics in more than 95% of MCL. 3;4 
Current treatment strategies include combinations of the monoclonal anti-CD20 antibody 
rituximab with different chemotherapy regimens as well as more intensive treatment 
protocols including high-dose ara-C.5-7 Furthermore, there is increasing evidence that 
autologous stem cell transplantation (ASCT) as part of the first-line treatment leads to a 
substantial prolongation of disease free survival (DFS) and OS in younger patients with 
MCL.8-14 Although in particular combinations of rituximab, ara-C-based consolidation and 
ASCT can achieve long-lasting remissions in significant proportions of patients, 7;10;15-18 
individual patients may still suffer from early relapse. Recent evidence suggests that clinical 
relapses which might be prevented by experimental consolidation treatments, such as 
interferon-alpha or antibody maintenance or even allogeneic SCT. Therefore prediction of 
quality and duration of response becomes increasingly important for early individual risk 
estimation. 
 
The MCL international prognostic index (MIPI) based on the 4 independent factors age, 
ECOG performance status, LDH and white blood cell (WBC) count is of proven value for pre-
treatment risk assessment in patients with advanced stage MCL.19 However, parameters for 
early response assessment and individual risk assignment during treatment are currently 
lacking.  
 
Molecular monitoring of minimal residual disease (MRD) by quantitative PCR is a broadly 
applicable tool for the assessment of circulating residual lymphoma cells with a great impact 
on prognosis in different B-cell lymphoma entities.20-27 We have shown that quantitative MRD 
assessment during treatment allows to compare the relative impact of different treatment 
modalities (i.e. conventional chemotherapy, ASCT, with and without monoclonal antibodies) 
on the tumor load, and to study the kinetics of tumor depletion and regrowth after cytotoxic 
treatment in MCL.26  Clonal IGH VH-JH rearrangements as well as the t(11;14) translocation 
are suitable targets for molecular MRD assessment in MCL.  Achievement of a molecular 
remission (MR) defined as achievement of MRD negativity following ASCT demonstrated a 
high prognostic significance for progression free survival (PFS) and OS in MCL.26 However, 
to date only sparse data on the prognostic impact of MRD in the setting of modern combined 
immuno-chemotherapy approaches are available10;11;26;28.  
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In the present study we therefore addressed the prognostic potential of quantitative MRD 
monitoring after combined immunochemotherapy followed by ASCT or maintenance 
treatment in MCL patients. Taking advantage of two large and homogeneously treated 
patient cohorts from the current Intergroup European MCL Network trials (MCL net), we 
evaluated the prognostic impact of MRD kinetics on disease control and compared the 
specific effect of different treatment modalities (combined immunochemotherapy, 
myeloblative radio-chemotherapy and maintenance treatment with interferon-α or rituximab) 
on quantitative MRD load.  
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Patients and methods 
Patients and sample collection for MRD 
Patients with histologically confirmed MCL were randomized within the clinical trials of the 
MCL net  according to age and eligibility to receive a high dose therapy. The trials were 
investigating the role of different induction protocols followed by either two different high-
dose regimens with ASCT (MCL Younger) or two different maintenance therapies (MCL 
Elderly). Inclusion criteria comprised patients up to 65 years of age in the MCL Younger trial 
and above 60 years in the MCL Elderly trial with previously untreated, advanced Ann-Arbor 
stage II to IV MCL. The histologic diagnosis was confirmed by a central pathology review at 
one of the designated pathology reference centers (European MCL Pathology Panel). Both 
protocols including the incorporated MRD analyzes had been approved by the local 
institutional review boards and were conducted according to the updated declaration of 
Helsinki, and are listed under www.clinicaltrials.gov (MCL Younger NCT00209222, MCL 
Elderly  NCT00209209). 
Prospective quantitative MRD monitoring was a pre-defined secondary objective of the 
current trials of the EU-MCL Network. However, participation in the MRD program was not a 
prerequisite for randomization in the clinical trials. MRD assessment was performed in 
national reference labs. Due to logistical reasons MRD assessment was mainly performed in 
Germany and France. Because this analysis was performed within ongoing trials, clinical and 
molecular data could not be collected concordantly in all cases. 
 
 
Histological, immunhistochemical and cytogenetic analyzes  
The diagnosis of MCL was established according to WHO criteria.29 Conventionally and 
immunohistochemically stained paraffin sections of lymph node biopsies were reviewed. 
Minimal requirements for immunohistochemistry included: positivity for Cyclin D1, CD20 and 
CD5, negativity for CD23 and CD10. The histological slides and immunohistochemical 
stainings (CD20, CD5, CD23, CyclinD1) were evaluated according to the Annecy criteria21 
and MCL were sub-classified according to the different cytological subtypes. Histological 
slides were reviewed by members of the European Mantle Cell Lymphoma Study Group.  
The presence of a t(11;14)(q13;q32) translocation was investigated by either PCR, FISH or 
conventional cytogenetics in diagnostic PB and/or BM samples.  
 
Treatment of patients below 65 years and eligible for ASCT 
After initial randomization patients received either 6 cycles of 3-weekly R-CHOP followed by 
stem cell mobilization with DexaBEAM and myeloablative radio-chemotherapy with 
autologous blood stem cell support according to a previously published protocol of the EU-
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MCL Study Group 14 or a total of 6 cycles of alternating R-CHOP/R-DHAP regimens with a 
high dose Ara-C containing myeloablative radio-chemotherapy and ASCT. 15;16 Following 
myeloablative therapy no further antilymphoma treatment was applied (figure 1). 
 
Treatment of patients above 65 years or above 60 and ineligible for ASCT 
Patients were randomized to induction treatment of either 8 cycles of 3-weekly R-CHOP or 6 
cycles of 4-weekly R-FC chemotherapy. After a second randomization all patients in clinical 
remission received maintenance treatment with either interferon-α (IFN-α 3x3 M IU or 
PegIntron 1 μg/kg weekly) or rituximab maintenance (rituximab 375 mg/m2) at 2-monthly 
intervals. Maintenance treatment was given until clinical relapse (figure 1).30 
 
Flow Cytometry  
Four-color flow cytometry (4C-FC) was performed to assess the proportion of MCL cells in 
diagnostic blood and bone marrow samples. 
This four-color flow cytometry assay had been previously standardized and tested in 281 
peripheral blood and bone marrow samples from 98 MCL patients of the current EU-MCL 
trials and demonstrated a high specifity and sensitivity for MCL cell quantification. The 
principles of staining protocols for flow cytometry, gating strategies as well as specifity and 
sensitivity have been recently published by our group in detail.31 
The degree of lymphoma involvement of the diagnostic sample was subsequently used to 
establish standard dilution series of the diagnostic specimen for real-time quantitative RQ-
PCR for each individual patient.  
 
 
Clonality assessment and PCR based MRD analysis 
DNA from PB or peripheral blood mononuclear cells (PBMC) and BM was extracted with a 
standard proteinase K digestion and a phenol-chloroform extraction or the Qiagen Blood Mini 
Kit (Qiagen, Hilden; Germany). Samples were analyzed by t(11;14) PCR and IGH multiplex 
PCR as published to assess the clonal rearrangement.32;33 Genescanning and sequence 
analyzes were performed on an ABI PRISM 377 automated sequencer (Applied Biosystems, 
Foster City, CA, USA). Sequencing of clonal rearrangements for allel-specific PCR was 
performed by using the BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied 
Biosystems). 
Quantitative PCR with allel-specific oligonucleotides was performed as described 
previously.26 The assays were established to reach a sensitivity of 10-5, tested by analyzing 
10-fold serial dilutions from diagnostic samples in polyclonal DNA derived from pooled 
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mononuclear cells of healthy donors. For determining the quantitative MRD levels target 
copy numbers were related to the number of target copies at diagnosis. 
 
MRD levels were given as fraction of numbers of MCL cells per total number of mononuclear 
BM or PB cells analyzed per PCR assay.  
Only follow-up samples with a minimum sensitivity of at least 1x10-4 according to albumin 
copies as control gene 34 were included in survival analysis. Results of RQ-PCR were 
evaluated according to the criteria of the European Study Group on MRD detection in ALL 
(ESG-MRD-ALL).35  
MRD status at a certain time point was assigned by investigating either PB or BM and if 
available both. In case of parallel investigations of PB and BM, MRD was judged positive if at 
least one of both samples was positive by RQ-PCR. A molecular remission was assigned as 
complete if both parallel samples were MRD negative. Within this study we used the pooled 
MRD information resulting from MRD analysis in PB and/or BM. In case of MRD positive 
parallel samples the higher MRD value was used for calculation. 
 
Response criteria and evaluation  
Clinical response was assessed after midterm induction therapy (3-4 cycles of induction 
therapy according to the protocol), at restaging after completion of induction therapy (about 4 
weeks after the last cycle of induction), 3 months after ASCT (within MCL Younger) and at 2 
to 3 monthly intervals during follow-up. As this analysis has been performed within ongoing 
clinical trials, randomized arms were pooled and analyzed together without any unblinding of 
the treatment arms. 
Response was defined according to the International Working Group criteria.36 Response 
duration (RD) was defined only for patients who achieved at least a PR after induction 
treatment and was calculated as period from the completion of induction to documented 
progression or death from any cause, which were both considered as an event. Overall 
survival (OS) was defined as the interval between trial registration and death from any cause.  
 
 
Definition of molecular remission and sampling time points for MRD analysis  
PB and/or BM samples were collected at diagnosis and at follow-up according to clinical 
staging time points. Sampling time points corresponded to clinical response assessment and 
included: midterm staging (after 3-4 cycles of induction therapy according to the protocol), 
restaging after completion of induction therapy (about 4 weeks after the last cycle of 
induction with R-CHOP or R-CHOP/R-DHAP or R-FC prior to DexaBEAM and ASCT or 
maintenance treatment) and post-induction monitoring at 3 monthly intervals after ASCT for 
MCL Younger patients and at 2 to 3 monthly intervals during maintenance follow-up for MCL 
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Elderly patients (figure 1). MRD monitoring was intended to be performed until clinical 
relapse in both trials. 
 
MRD status at a certain time point was assigned by using the pooled MRD information from 
MRD analysis in PB or BM and if available both. In case of parallel investigation of PB and 
BM, MRD was judged positive if at least one of both samples was positive by RQ-PCR. In 
case of MRD positivity in parallel samples the higher MRD value was used for calculation.  
Molecular remission (MR) was defined as MRD negativity investigated by clone-specific RQ-
PCR with an assay sensitivity of at least 10-4. MR was assigned in parallel analyzed PB and 
BM samples if both were MRD negative.  
MRD status within the post-induction period (implying for MCL Younger patients the first 12 
months after ASCT and for MCL Elderly patients the first 12 months after end of 
induction/start of maintenance) a patient was judged to be MRD positive if at least one 
sample demonstrated MRD positivity by RQ-PCR.  
Samples collected at or subsequent to documented clinical relapse were not included in 
statistical analysis.  
 
Statistical analysis  
To describe quantitative MRD-values median and ranges of MRD levels were assessed. 
Quantitative MRD-values were compared between groups according to baseline 
characteristics using the Mann-Whitney-U-Test. Quantitative MRD-values in PB and BM 
were compared with Pearson’s r and the concordance correlation coefficient. 37 Quantitative 
MRD-values at different time points during induction were compared by Wilcoxon rank-sum-
test. Cross-tables together with exact Fisher tests were calculated to assess the association 
of the achievement of a molecular remission with categorical clinical parameters and with 
clinical response. MR after induction and during the first year of follow-up was compared in 
paired samples by McNemar’s test. Response duration according to clinical or molecular 
remission was analyzed by Kaplan-Meier estimates and compared using the log rank test. 
Follow-up time was estimated using the reversed Kaplan-Meier method. Multiple Cox 
regression was performed to analyze the adjusted prognostic value of molecular remission in 
a model together with clinical remission status and MIPI prognostic score at diagnosis. The 
significance level was 5%. Statistical analyzes were performed using SAS 9.1, SAS Institute 
Inc., Cary, NC, USA. 
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Results  
Patients and samples 
From 01/01/2004 until 16/10/2008 760 patients with central review-confirmed MCL were 
randomized within the intergroup trials of the MCL net, 600 of these in Germany (n=356) and 
France (n=244) (figure S1).  
Sample recruitment for MRD (at least one sample) comprised 90% of all study patients 
recruited in Germany and France. In the missing 10% samples were not send according to 
lacking center or patient compliance because MRD assessment was not a prerequisite for 
study enrolment. As of October 2008, 259 patients with a molecular marker and at least 2 
samples from different time points had been analyzed for MRD, comprising 160 patients 
treated within the European MCL Younger trial and 99 patients within the MCL Elderly  trial 
(figure S2).  
The detection of a suitable molecular marker for RQ-PCR was possible in 90% of all patients 
with material available for MRD. In case of patients with diagnostic samples not-informative 
for molecular follow-up, this was principally due to failure to identify a clonal IGH population. 
MRD was assessed with quantitative allele specific IGH-RQ-PCR (n = 245) or allele specific 
IGH-BCL- RQ-PCR (n = 14).  
Patients analyzed for MRD did not differ from those of the complete study cohort with respect 
to clinical characteristics (table 1). Overall 315 samples prior to treatment (210 PB, 105 BM) 
and 1324 follow-up samples (907 PB, 417 BM) were investigated. All 315 baseline samples 
demonstrated lymphoma infiltration by RQ-PCR. 
 
assessment available as well as a suitable molecular marker for RQ-PCR. Central.As 
prospective quantitative MRD monitoring was a pre-defined secondary objective of the 
current intergroup trials of the MCL net, French and german patients patients with central 
review-confirmed MCL randomized to one of the current trials from 01/01/2004 until 
16/10/2008 who had samples for central MRD monitoring available were investigated for the 
presence of a clonal marker for RQ-PCR at diagnosis. 
 
 
 
Comparability of PB and BM for MRD detection  
With regard to the ease of access to MRD samples in clinical routine we addressed the 
question of comparability of PB and BM for MRD assessment. At diagnosis, 95 paired BM 
and PB samples demonstrated similar levels of lymphoma cells with a median level of 
7.1x10-2 in BM and 5.6x10-2 in PB (Pearson r=0.82, concordance correlation coefficient 
c=0.81).   
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After induction, 31 of 108 paired samples were concordantly positive in PB and BM and 50 
were negative in both. In 21 paired samples discordant results were obtained with MRD 
negative PB but low-level MRD detectable in the corresponding BM. In contrast, only 6 BM 
samples failed to demonstrate persistent disease when the corresponding PB sample was 
MRD positive. Thus, PB analysis after induction underestimated MRD in about 19% of 
patients.  
 
Kinetics of MRD 
Circulating lymphoma cells (CLC) were assessed by using 4C-FC in 157 of 210 patients with 
available peripheral blood at diagnosis. Due to different sample processing peripheral blood 
samples of 53 patients were not directly accessible for CLC by 4C-FC.  
Although the vast majority had no leukemic MCL by clinical parameters, all 157 patients 
showed CLC at a median level of 6.3x10-2 (range 2.0x10-4 to 8.3x10-1). Levels of CLC 
correlated significantly with the following parameters: stage (median 5.4x10-3 stage 2, 2.4x10-
2
 stage 3 and 7.6x10-2 stage 4, p=0.0023), elevated LDH (1.2x10-1 vs. 4.7x10-2, p= 0.0021), 
histological BM infiltration (7.8x10-2 vs. 1.9x10-2 p=0.0002) and MIPI prognostic index 
(2.7x10-2 vs. 7.9x10-2 vs. 3.3x10-1 for low, intermediate and high risk respectively, p<0.0001) 
(figure S3).  
Monitoring of MRD kinetics during induction was possible in 190 patients and showed that 
induction treatment with combined immunochemotherapy protocols rapidly reduced the 
tumor cell load. At midterm staging, 59/190 (31%) patients achieved a MR corresponding to 
a median 3-log tumor cell reduction (figure 2). The median lymphoma cell level prior to 
treatment were comparable in PB and BM samples (6.2x10-2 compared to 7.1x10-2 (range 
2.0x10-4 to 9.0x10-1 in BM and 8.3x10-1 in PB) and were significantly reduced to a median of 
1.0x10-4 in PB and 1.2x10-4 in BM at midterm staging (p<0.0001) and to MRD negativity at 
end of induction in both (p<0.0001) (figure 2). 
 
Clinical response to treatment 
207/259 patients with MRD data were evaluable for clinical response after induction with 65 
patients (31%) achieving a CR and 135 patients achieving a CRu or PR (ORR 97%). For 
patients of the MCL Younger and MCL Elderly trial the CR rate was 32% and 31%, and the 
ORR 99% and 95%, respectively. To date, 27 patients relapsed (12 in MCL Younger and 15 
in MCL Elderly) and 5 patients died in remission (one in MCL Younger and 4 in MCL Elderly). 
With a median observation time of 17 months, the median response duration has not been 
reached with 75% patients in remission at 2 years (MCL Younger: median response duration 
not reached, patients in remission at 2 years 84%; MCL Elderly median response duration 37 
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months, patients in remission at 2 years 58%). Of 225 patients evaluable for overall survival 
26 have died, with median OS not reached and 2 years OS of 86%.  
 
Achievement of Molecular Remission 
Molecular remission (MR) after induction treatment was achieved by 106 of 190 patients with 
MRD data (56%). Interestingly, MCL Elderly patients achieved a MR (54/81, 67%) more 
frequently compared to MCL Younger patients (MR 52/109, 48%) (p=0.012) despite a higher 
number of patients with an adverse MIPI score (MIPI high risk 49% vs. 12%).  
MRD persistence after induction correlated with the following pretreatment parameters: stage 
(0%, 36%, 47% positive for stages II, III, and IV respectively, p=0.04), the presence of B-
symptoms (53% vs. 38%, p=0.051), LDH above normal level (55% vs. 38%, p=0.024) and 
BM infiltration (49% vs. 25%, p=0.015). Patients achieving a clinical CR and CRu had a 
higher probability of obtaining a MR (both 70%) than patients achieving a PR (42%, 
p=0.0018).  
 
Prognostic relevance of Molecular Remission 
One hundred and fifty-six patients with MRD data and a documented clinical remission after 
induction were evaluable for assessment of the prognostic impact of MRD (figure S2). 
Patients achieving a MR after induction (n=87) demonstrated a significantly improved 
response duration compared to patients with residual disease (n=69) (patients in remission 
at 2 years 87% vs. 61%, p=0.0043) (figure 3a).  
The high impact of MR on response duration was also confirmed when only PB was 
analyzed (147 patients, patients in remission at 2 years: 88% for MRD negative patients 
compared to 64% of MRD positive patients, p=0.0009) (figure 3b). 8/97 (8%) patients in the 
PB-MRD negative cohort relapsed compared to 12/50 (24%) patients in the MRD positive 
group. The impact of MRD was even more prominent when only BM was assessed (n=91, 
patients in remission at 2 years 94% in MRD negative vs. 58% in MRD positive patients, 
p=0.0002, figure 3c). Only one patient relapsed in the BM-MRD negative group compared to 
11 patients with detectable residual disease.  
We also compared the significance of MRD in PB and BM within the clinical response 
groups after induction (CR/Cru and PR). Notably, MRD status in PB and BM was a much 
better predictor for response duration than the clinical response status (CR/CRu/PR). MR in 
the BM correlated with a significant prolongation of response duration compared to MRD 
positive CR or MRD positive CRu/PR patients (patients in remission at 2 years: 94% in MRD 
negative CR/Cru and 100% in MRD negative PR, compared to 71% in MRD positive CR/Cru 
and 51% in MRD positive PR, p=0.0023, (figure 4). This was also reproducible when PB 
alone was investigated (patients in remission at 2 years: 92% in MRD negative CR/Cru and 
83% in MRD negative PR, compared to 85% in MRD positive CR/Cru and 55% in MRD 
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positive PR, p=0.0029) (data not shown)  
MRD was prognostically significant independent of assignment to the MCL Younger or MCL 
Elderly trial. MRD negativity after induction was reached in 46/91 evaluable MCL Younger 
patients and 41/65 MCL Elderly patients and was associated with a better prognosis in both 
cohorts (MCL Younger: patients in remission at 2 years: 94% vs. 74%, p=0.0216, figure 5, 
MCL Elderly: 77% vs. 34%, p= 0.0207, figure 6). In both trials the impact of MRD on 
prognosis was confirmed when PB as well as BM was analyzed (figures S4 to S7). 
A Cox regression model was used to evaluate the prognostic significance of MR together 
with achievement of CR/CRu vs. PR and pretreatment clinical variables summarized in the 
continuous MIPI score. Achievement of a MR after induction (HR 0.4, 95%CI 0.1-0.9, 
p=0.027) turned out to be an important prognostic factor for response duration independent 
from MIPI (HR 3.2, 95%CI 1.8-5.6, p<0.0001) and achievement of CR (HR  0.7, 95%CI 0.2-
2.0, p=0.49). 
 
MRD assessment in the post-induction period  
Within both trials MRD assessments were performed at 2 to 3 monthly intervals during the 
first 12 months of the post-induction period (after ASCT in MCL Younger patients and during 
maintenance in MCL Elderly patients) to evaluate the prognostic impact of a sustained 
molecular remission. MRD data were pooled from a median of 3 (1 to 8) samples and the 
MRD status was judged as MRD positive if at least one sample was positive by RQ-PCR.  
 
Amongst 60 MCL Younger patients all 41 patients with a consistently negative MRD status 
within the first year after ASCT remained in continuous clinical remission whereas 5/19 
patients with at least one MRD positive sample within this period relapsed (patients in 
remission at 2 years 100% vs. 65%, medians not reached, p=0.0007) (figure 7). This was 
also confirmed when either only PB (n=57, p=0.0039)  or only BM (n=37, p=0.0142 were 
assessed for the presence of MRD (data not shown). 
Similarly, in 51 MCL Elderly patients a consistently negative MRD status during the first year 
of maintenance was associated with a prolonged response duration, 76% of patients in MR 
were in clinical remission at 24 months compared to only 36% of the patients with residual 
disease (p=0.015) (figure 8).  
For younger and elderly patients the impact of sustained MRD-negativity could be confirmed 
in landmark analysis. Only patients in ongoing clinical remission at the respective time point 
3, 6 and 12 months after induction treatment (MCL Elderly trial) or ASCT (MCL younger trial) 
were included in this analysis demonstrating that during all 3 time periods a sustained 
molecular remission retains its high clinical significance  (FS8-S13) 
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Hence, these results demonstrate that a consistently negative MRD status in patients 
achieving clinical remission has a strong impact on prognosis independent from the 
treatment regimen that was applied to achieve it.   
 
 
Impact of high-dose treatment on Molecular Remission 
A direct comparison of the impact of high-dose treatment followed by ASCT on tumor cell 
reduction could be performed in 67 MCL Younger patients with DNA available after induction 
treatment and after ASCT. Amongst 67 MCL Younger patients, 37 were MRD negative after 
induction treatment (55%). High-dose treatment followed by ASCT increased the MR rate to 
72% (48/67, p = 0.0116, Mc Nemar test) demonstrating a significant impact of high-dose 
treatment on tumor reduction.  
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Discussion 
 
Today, a spectrum of highly effective but potentially toxic treatment modalities is available for 
patients with MCL. This makes sensitive and reliable assessment of treatment efficacy 
allowing individual estimation of response duration desirable in order to optimize patient care 
as well as trial design. Previous retrospective data from our group suggested that 
quantitative measurement of MRD during and after treatment may provide an excellent tool 
to achieve this objective.26 
Those earlier MRD data were in keeping with the notion that persistence of residual 
lymphoma cells is considered to be the principal reason for relapse 21;23. However, in those 
earlier series patients did not receive rituximab as a part of induction treatment. We 
hypothesized that MRD assessment as a dynamic parameter might contribute to the 
prediction of prognosis, independently from pretreatment risk profile (MIPI score). This 
analysis was particularly important as previous data addressed this question retrospectively 
in small patient cohorts only. 21;23;26 
The aim of our study was therefore (1) to assess the prognostic relevance of MRD in the 
context of two large prospective trials investigating various immunochemotherapy regimens 
with different consolidation treatments, and (2) to study the individual effects of different 
treatment components on response kinetics and tumor load in MCL patients. 
 
Because of easier access and patient comfort MRD analysis of PB would be preferable to 
BM assessment. This is of particular importance as rituximab based treatment protocols 
induce profound peripheral B-cell depletion that might lead to a discordant PB MRD status in 
comparison with the clinical disease status and prognosis may be altered by prior Rituximab 
use due to a preferential clearance of disease from the PB compartment. 
Therefore we addressed the question of the comparability of both sources for MRD 
assessment prior to and after combined immunochemotherapy. By analyzing 95 paired PB 
and BM pre-treatment samples we found comparable median CLC levels in PB and BM. 
However, the situation changes when paired samples after start of immunochemotherapy 
were compared. Analysis of PB alone failed to demonstrate persistent lymphoma cells in 
about 19% of patients who were simultaneously positive in BM. We thus demonstrate herein 
that rituximab-based immunochemotherapy more effectively clears lymphoma cells from PB 
than from BM. This phenomenon has been reported for alemtuzumab administered in CLL38 
but is in contrast to our earlier findings in MCL demonstrating a similar predictive value of 
MRD assessment in PB or BM also after rituximab-free treatment. 26 Accordingly, in the 
present study BM MR predicted more accurately for an event-free clinical course than PB 
MR although even the latter was associated with a clearly superior outcome. Therefore, 
source of material for MRD assessment remains an important issue which must be taken 
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into account when designing clinical trials or using MRD results as basis for consolidation or 
preemptive treatment decisions. 
In this study MRD assessment allowed for the first time direct evaluation of the impact of 
individual treatment elements on tumor cell reduction within a multimodal protocol in patients 
with MCL. Immunochemotherapy rapidly caused a median MRD reduction of 3 log by 
midterm staging and induced MR in 56% of the cases after end of induction. This is in 
marked contrast to our previous work showing that 4-6 cycles of CHOP alone did not 
significantly reduce MRD levels, and none of those patients achieved MR after induction 26. 
This observation correlates with the superior clinical response rate of R-CHOP over CHOP in 
MCL 5 but can also be influenced by the potential effect of the different induction regimens 
that are tested within the two trials (R-DHAP and R-FC). Thus, our data suggest that 
rituximab improves the efficacy of CHOP chemotherapy that on its own shows only limited 
activity in MCL.  
With regard to prediction of prognosis achievement of MR after induction was highly 
correlated with prolonged response duration independent of the study protocol applied. A 
favorable outcome could be predicted early by MRD assessment of PB or preferably BM at a 
single time point after induction. Thus, achieving MR after induction is clearly a desirable 
goal in the treatment of patients with MCL. It remains unclear, however, if the better 
sensitivity to cytotoxic treatment as documented by achievement of MR simply reflects a 
more “benign” biological profile of the tumor in individual patients, or if MR has prognostic 
impact per se. 
 
Our results are in contrast to published data suggesting that achievement of MR in MCL after 
rituximab and CHOP or other chemotherapy schemes has no impact on prognosis 39. 
Although in the study by Howard et al. 9/25 patients with PCR-detectable disease at 
diagnosis achieved a molecular remission, no differences in outcome according to MRD 
status could be demonstrated. This can in part be explained by the small numbers of 
patients but also by technical aspects. Most previous reports on MRD detection within 
multimodal treatment protocols were based on qualitative PCR approaches that appear  less 
reliable for PCR-based risk stratification in MCL due to varying sensitivity and the lack of 
standardized evaluation. Thus, our results underline once more the importance of highly 
standardized, sensitive and quantitative RQ-PCR assays for MRD assessment 26 as this has 
already been documented previously by our group. 
 
Quality of clinical remission after treatment is thought to be one of the strongest parameters 
for prognosis in patients with MCL 5;13;40. Of note, in this series the prognostic impact of MR 
in responding patients exceeded that of clinical remission status. Patients achieving a MRD-
negative CR or PR had a response duration which was superior to that of patients with a 
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MRD-positive CR or PR. This implies that prediction of outcome by MRD is much more 
meaningful than by quality of clinical remission and strongly suggests that future treatment 
protocols should incorporate MRD assessment in response evaluation of MCL treatment.  
Similar observations on the prognostic impact of MRD have recently been reported in CLL 
where a MRD-negative status was the strongest predictor of clinical outcome superior to 
quality of 41;42 response or low level of MRD during and after induction were identified as 
prognostic parameter for PFS. 43  Also in MCL it will be useful to investigate the prognostic 
value of different MRD cut-offs in PCR positive patients to precisely define clinical risk 
groups. 
 
In a multivariate analysis including the parameters MIPI and quality of clinical response in 
addition to MRD the achievement of MR after induction turned out to be an independent 
prognostic factor for response duration. These results document for the first time the 
independent prognostic value and high clinical relevance of MRD after combined 
immunochemotherapy in MCL. Comparable results in a prospective series have only been 
published in patients in follicular lymphoma undergoing treatment with 6 courses of CHOP 
followed by rituximab (CHOP-R) or -supplemented high-dose sequential chemotherapy with 
autografting (R-HDS). In this entity molecular remission was achieved in 44% of R-CHOP 
and 80% of R-HDS patients (P <0.001) 25 representing the strongest predictor of outcome.  
 
MRD kinetics was also analyzed in the post-induction period, after ASCT consolidation in 
MCL Younger patients and during maintenance treatment in MCL Elderly patients.  
In younger patients MRD kinetics clearly demonstrated that high-dose radio-chemotherapy 
followed by ASCT can further reduce the tumor load even if applied immediately after 
immunochemotherapy. The rate of MR increased from 55% post-induction to 72% within the 
first year after ASCT. These data impressively demonstrate the anti-lymphoma activity of 
high-dose radio chemotherapy in MCL as already inferred from clinical data 9;10;13;14 and our 
previous observations 26. On the other hand, patients in whom neither rituximab containing 
induction nor the high-dose consolidation induced MR had a significantly inferior outcome. 
This might suggest that for future clinical trials the post-ASCT rather than the post-induction 
MRD status is an excellent tool for identifying patients in need for further treatment 
intensification or consolidation. However, the post-induction MRD status has the advantage 
of providing the prognostic information more timely, thereby allowing for better planning of 
potential post-consolidation treatment intensification or maintenance treatment.  
 
In summary, the addition of rituximab into the treatment of MCL has clearly improved the 
outcome of patients with MCL as shown by several trials10-12. The present study 
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demonstrates for the first time, that prospective longitudinal monitoring of MRD after 
combined immunochemotherapy can be a powerful predictor of treatment outcome in 
patients with MCL allowing an early individual risk assessment already during treatment. 
Accordingly, MRD assessment should be integrated into future clinical trial concepts to 
evaluate new treatment strategies and to serve as an early surrogate marker that can be 
used for risk adapted treatment.  
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Table 1 : Baseline clinical characteristics 
 
  all 
cohort analyzed for 
MRD  
MCL Younger 
 
MCL Elderly 
 
Variable Value n=259 n=160 n=99 
Age (years) median 
(range) 
61 (33-81) 55 (33-65) 70 (60-81) 
Sex Male 77% 81% 71% 
stage 2 2% 1% 4% 
 3 14% 15% 12% 
 4 84% 84% 84% 
B-symptoms Yes 39% 39% 39% 
LDH Elevated 39% 38% 41% 
Extra nodal Yes 34% 37% 29% 
Bone marrow yes 81% 83% 79% 
MIPI risk Low Risk 43% 65% 8% 
 Intermediate 
Risk 
34% 23% 52% 
 High Risk 23% 12% 40% 
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Figure 1 A and B: Diagram of the two randomized EU-MCL network trials. (A) MCL 
Younger and (B) MCL Elderly with the respective MRD sampling time points. MRD is 
assessed until clinical relapse or death. Maintenance treatment in both arms of the elderly 
protocol is given until progression or death. 
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P B S C
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alternating 3-weekly
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R-CHOP  3-weekly
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MRD MRD 2-3 monthly intervals
(A)
R-FC Induction
6 cycles  4-weekly
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1 95 13 17 21week
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R-CHOP Induction
8 cycles 3-weekly  
Rituximab maintenance
R
Interferon maintenance
R
Rituximab maintenance
R
Interferon maintenance
MRD MRD 2-3 monthly intervals
(B)
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Figure 2: MRD quantification by RQ-PCR of 190 patients prior to, during and after 
induction. Combined immunochemotherapy resulted in a significant 3 log reduction of 
lymphoma cells in PB and BM from 6.2x10-2 in PB and 7.0x10-2 in BM prior treatment to 
1.0x10-4 in PB and 1.2x10-4 in BM at midterm staging (p<0.0001) and to MRD negativity after 
end of induction (prior to DexaBEAM/ASCT or maintenance). Filled black symbols for MRD 
positive samples, empty symbols for MRD negative samples. 
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Figure 3a: Response duration according to MRD status after combined 
immunochemotherapy. MRD was assessed in PB and/or BM after end of induction in MCL 
Younger and MCL Elderly patients.   
 
 
Figure 3b: Response duration according to MRD status assessed in the peripheral 
blood after induction with combined immunochemotherapy. MRD was assessed in MCL 
Younger and MCL Elderly patients.   
 24
 
 
Figure 3c: Response duration according to MRD status assessed in the bone marrow 
after induction with combined immunochemotherapy. MRD was assessed in MCL 
Younger and MCL Elderly patients.   
 25
  
 
 
Figure 4: Response duration according to MRD status and clinical remission 
(CR/Cru/PR). MRD was assessed in the bone marrow after induction with combined 
immunochemotherapy in MCL Younger and MCL Elderly patients.   
 
 
 
 
 
Figure 5: Response duration according to MRD status assessed in PB and/or BM after 
induction with combined immunochemotherapy in MCL Younger patients.   
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Figure 6: Response duration according to MRD status assessed in PB and/or BM after 
induction with combined immunochemotherapy in MCL Elderly patients.   
 
 
 
 
 
Figure 7: Response duration according to MRD status assessed in PB and/or BM 
within the first 12 months after ASCT in MCL Younger patients. MRD status was judged 
as MRD positive if at least one sample of in median 3 was positive. 
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Figure 8: Response duration according to MRD status assessed in PB and/or BM 
during the first year of maintenance in MCL Elderly patients.   
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